Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis

Summary

Urgent reversal of warfarin is required for patients who experience major bleeding or require urgent surgery. Treatment options include the combination of vitamin K and coagulation factor replacement with either prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP). However, the optimal reversal strategy is unclear based on clinically relevant outcomes. We searched in MEDLINE, EMBASE and Cochrane library to December 2015. Thirteen studies (5 randomised studies and 8 observational studies) were included. PCC use was associated with a significant reduction in all-cause mortality compared to FFP (OR= 0.56, 95 % CI; 0.37–0.84, p=0.006). A higher proportion of patients receiving PCC achieved haemostasis compared to those receiving FFP, but this was not statistically significant (OR 2.00, 95 % CI; 0.85–4.68). PCC use was more likely to achieve normalisation of international normalised ratio (INR) (OR 10.80, 95 % CI; 6.12–19.07) and resulted in a shorter time to INR correction (mean difference –6.50 hours, 95 %CI; –9.75 to –3.24). Red blood cell transfusion was not statistically different between the two groups (OR 0.88, 95 % CI: 0.53–1.43). Patients receiving PCC had a lower risk of post-transfusion volume overload compared to FFP (OR 0.27, 95 % CI; 0.13–0.58). There was no statistically significant difference in the risk of thromboembolism following administration of PCC or FFP (OR 0.91, 95 % CI; 0.44–1.89). In conclusion, as compared to FFP, the use of PCC for warfarin reversal was associated with a significant reduction in all-cause mortality, more rapid INR reduction, and less volume overload without an increased risk of thromboembolic events.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Factor concentrates - haemorrhage - warfarin - mortality - plasma

• References

• 1 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
• 2 Chai-Adisaksopha C, Hillis C, Isayama T. et al. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2015; 13: 2012-2020.
• 3 Investigators TSPiAF. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409-416.
• 4 Agnelli G, Prandoni P, Santamaria MG. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345: 165-169.
• 5 van der Meer FJ, Rosendaal FR, Vandenbroucke JP. et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153: 1557-1562.
• 6 Healey JS, Eikelboom J, Douketis J. et al. Periprocedural bleeding and throm-boembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-348.
• 7 Reutter JC, Sanders KF, Brecher ME. et al. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apher 2001; 16: 134-138.
• 8 Toy P, Popovsky MA, Abraham E. et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33: 721-726.
• 9 Nelson KE, Donahue JG, Munoz A. et al. Transmission of retroviruses from se-ronegative donors by transfusion during cardiac surgery A multicentre study of HIV-1 and HTLV-I/II infections. Ann Intern Med 1992; 117: 554-559.
• 10 Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol 2003; 10: 412-418.
• 11 Selik RM, Ward JW, Buehler JW. Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982 through 1991. Transfusion 1993; 33: 890-893.
• 12 Goodnough LT. A reappraisal of plasma, prothrombin complex concentrates, and recombinant factor VIIa in patient blood management. Crit Care Clin 2012; 28: 413-426 vi-vii.
• 13 Dentali F, Marchesi C, Giorgi Pierfranceschi M. et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists A meta-analysis. Thromb Haemost 2011; 106: 429-438.
• 14 Holbrook A, Schulman S, Witt DM. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) Suppl e152S-84S.
• 15 Keeling D, Baglin T, Tait C. et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154: 311-324.
• 16 Pernod G, Godier A, Gozalo C. et al. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010; 126: e167-174.
• 17 Morgenstern LB, Hemphill 3rd JC, Anderson C. et al. Guidelines for the management of spontaneous intracerebral haemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41: 2108-2129.
• 18 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-94.
• 19 Higgins JP, Altman DG, Gotzsche PC. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Br Med J 2011; 343: d5928.
• 20 Sterne JAC JPTH, Reeves BC. A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI). Version 1.0.0, 24 September 2014. Available from http://www.riskofbias.info Accessed January 15, 2016.
• 21 Higgin JPTGS. Cochrane Handbook for Systematic Review of Interventions. Version 5.1.0 [updated March 2011]. ed The Cochrane Collaboration; 2011
• 22 Brok J, Thorlund K, Gluud C. et al. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008; 61: 763-769.
• 23 Wetterslev J, Thorlund K, Brok J. et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61: 64-75.
• 24 Guyatt GH, Oxman AD, Kunz R. et al. What is „quality of evidence” and why is it important to clinicians?. Br Med J 2008; 336: 995-998.
• 25 Balshem H, Helfand M, Schunemann HJ. et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401-406.
• 26 Boulis NM, Bobek MP, Schmaier A. et al. Use of factor IX complex in warfarin-related intracranial haemorrhage. Neurosurgery 45: 1113-1119.
• 27 Demeyere R, Gillardin S, Arnout J. et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010; 99: 251-260.
• 28 Sarode R, Milling Jr TJ, Refaai MA. et al. Efficacy and safety of a 4-factor pro-thrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128: 1234-1243.
• 29 Goldstein JN, Refaai MA, Milling Jr TJ. et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015; 385: 2077-2087.
• 30 Fariborz Farsad B, Golpira R, Najafi H. et al. Comparison between Prothrombin Complex Concentrate (PCC) and Fresh Frozen Plasma (FFP) for the Urgent Reversal of Warfarin in Patients with Mechanical Heart Valves in a Tertiary Care Cardiac Centre. Iran J Pharm Res 2015; 14: 877-885.
• 31 Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagu-lation after intracerebral haemorrhage. Stroke 1992; 23: 972-977.
• 32 Cartmill M, Dolan G, Byrne JL. et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14: 458-461.
• 33 Takahashi A, Kato TS, Oda N. et al. Prothrombin complex concentrate for rapid reversal of warfarin-induced anticoagulation and intracerebral haemorrhage in patients supported by a left ventricular assist device. Int J Gerontol 2010; 04: 143-147.
• 34 Hickey M, Gatien M, Taljaard M. et al. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation 2013; 128: 360-364.
• 35 Majeed A, Meijer K, Larrazabal R. et al. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost 2014; 111: 233-239.
• 36 Karaca MA, Erbil B, Ozmen MM. Use and effectiveness of prothrombin complex concentrates vs fresh frozen plasma in gastrointestinal haemorrhage due to warfarin usage in the ED. Am J Emerg Med 2014; 32: 660-664.
• 37 Parry-Jones AR, Di Napoli M, Goldstein JN. et al. Reversal strategies for vitamin K antagonists in acute intracerebral haemorrhage. Ann Neurol 2015; 78: 54-62.
• 38 Ortmann E, Besser MW, Sharples LD. et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 2015; 121: 26-33.
• 39 Johansen M, Wikkelso A, Lunde J. et al. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev 2015; 07: CD010555.
• 40 Khorsand N, Veeger NJ, Muller M. et al. Fixed versus variable dose of prothrom-bin complex concentrate for counteracting vitamin K antagonist therapy. Trans-fus Med 2011; 21: 116-123.
• 41 Khorsand N, Veeger NJ, van Hest RM. et al. An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica 2012; 97: 1501-1506.